From Elad Katz’s experience

Benchmarking drug efficacy in 3D disease models with quantitative imaging

Elad directed translational 3D disease-modeling teams across oncology, cardiac, renal and fibrotic indications and developed custom quantitative image-analysis pipelines to benchmark drug efficacy.

Industry
Health and life sciences
Elad’s role
Led translational 3D disease-modeling teams

The business need

Benchmarking a drug's efficacy in a 3D disease model calls for quantitative measures of how the tissue responds. A treatment can change a tissue's shape and structure as well as its size, and measures of volume or of flat 2D sections can miss that.

Elad's teams worked on this across oncology, cardiac, renal and fibrotic indications.

What Elad did

  1. Directed translational 3D disease-modeling teams across oncology, cardiac, renal and fibrotic indications.
  2. Developed custom quantitative image-analysis pipelines to benchmark drug efficacy in those models.
  3. Published, as first author, an analytical approach that distinguishes individual from collective cancer invasion (Analytical Cellular Pathology, 2011).
  4. Co-authored a method to determine tamoxifen sensitivity using primary breast-cancer tissue in collagen-based 3D culture (Biomaterials, 2012).
  5. As corresponding author of a 2013 Disease Models & Mechanisms paper, applied 3D morphometrics (Minkowski functionals) to 3D images of tumors grown in culture to characterize their response to tamoxifen.

Technology and approach

  • Custom quantitative image-analysis pipelines
  • 3D morphometrics using Minkowski functionals on 3D imaging data
  • Collagen-based 3D culture of primary breast-cancer tissue
  • Optical projection tomography of long-term cultures of human breast-cancer specimens

Outcome

  • In the 2013 study, HER2 status predicted changes in tumor shape beyond volume after tamoxifen treatment, and the measures could partly predict tumor grade.

Decisions this experience speaks to

  • We're building a drug discovery or disease-modelling platform and aren't sure it's compatible with how pharma and biotech customers actually run their screening workflows - how do we find out?
  • We have promising preclinical data, but we don't know if it's strong enough, or the right kind of evidence, to support a partnership or licensing conversation?

Related services and use cases

Sources

  1. Elad Katz’s profile on CTO Grand Rounds
  2. Characterising the tumour morphological response to therapeutic intervention - University of St Andrews Research Portal (opens in a new tab)
  3. Publications by Elad Katz - PubMed (opens in a new tab)